- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
This study is looking at a new combination of treatments, AFM24 and Atezolizumab, for certain advanced cancers that have a specific marker (EGFR). We want to find out if it's safe, how it works in the body, and if it can shrink these cancers.
For: Advanced/Metastatic EGFR-expressing CancersPoland · Spain - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - Active not recruitingPHASE2
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
This study looks at new ways to help patients with stomach or gullet cancer after their regular chemotherapy. It tests if different medicines or close monitoring can keep the cancer under control for longer.
For: Adenocarcinoma of the Oesophagus · Adenocarcinoma of the Gastro-oesophageal Junction · Adenocarcinoma of the StomachUnited Kingdom - Active not recruitingPHASE2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
This study looks at new treatments (ramucirumab or merestinib) combined with standard chemotherapy for people with advanced biliary tract cancer. It aims to see how well these new drug combinations work and if they are safe.
For: Biliary Tract Cancer · Metastatic Cancer · Advanced CancerUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I4T-MC-JVCY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
This study looks at a new combination of treatments for advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). Researchers want to see if adding a drug called ramucirumab to erlotinib helps people live longer without their cancer getting worse, compared to erlotinib alone.
For: Metastatic Non-Small Cell Lung CancerSpain - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
For: Metastatic Non-Small Cell Lung CancerUnited States · Canada · France - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
For: Gastric Cancer, Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaArgentina · Belgium · Brazil - Active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Gastric AdenocarcinomaUnited States · Australia · Belgium